Recent studies have shown that mastoparan, an amphiphilic peptide derived from wasp venom, accelerates guanine nucleotide exchange and GTPase activity of purified GTP-binding proteins. In the present study we phosphates. Mastoparan-induced secretion was unaffected by preincubation with either the protein kinase C inhibitor staurosporine (10 nM-I0 uM) or prostacyclin (PGI2; 100 ng/ml) and was not accompanied by phosphorylation of the 45 kDa protein kinaseW C, substrate or the-20 4cba protein normally associated with platelet activation. The G-protein inhibitor guanosine 5'-[fl-thio]diphosphate (GDP[S]; 1 mM) attenuated the secretion induced by mastoparan in both intact and saponin-permeabilized platelets. Encapsulation of GDP[S] during reversible permeabilization inhibited mastoparaninduced secretion, providing evidence for an intracellular action of GDP [S]. In all these studies thrombin (0.05-0.2 unit/ml) elicited characteristic responses, and thrombin-induced secretion was inhibited by staurosporine, PGI2 and GDP [S]. Mastoparan also increased intra-platelet cyclic AMP in a dose-dependent manner. Mastoparan and PGI2 increased 32P incorporation into a protein of approx. 24 kDa, whereas phosphorylation of a 50 kDa substrate was only seen in PGI2-stimulated platelets. These results indicate that mastoparan promotes secretion by a mechanism which does not involve stimulation of phospholipase C and suggest that the secretory event may result either from a direct fusogenic action of mastoparan and/or from stimulation of the putative exocytosis-linked G-protein, Ge.
INTRODUCTION
The amphiphilic tetradecapeptide mastoparan (Ile-Asn-LeuLys-Ala-Leu-Ala-Ala-Leu-Ala-Lys-Lys-Ile-Leu-NH2) is a component of wasp venom which has been reported to exhibit diverse pharmacological effects on several biochemical processes in a variety of cell types. These include the activation in vitro of phospholipase A2 [1] and the ability to antagonize calmodulin activity [2] . Current interest in this compound has arisen from its recently described effects on purified GTP-binding proteins (Gproteins), where mastoparan has been shown to accelerate both nucleotide exchange and the subsequent GTP hydrolysis [3, 4] . It has therefore been proposed that the cellular effects of mastoparan, and other amphiphilic peptides [5] , are due to an ability to mimic G-protein-linked agonist-liganded receptors [3] .
There have been several reports of the effects of mastoparan in intact and permeabilized cells, and the peptide has been shown to promote exocytosis of histamine from mast cells [6] , 5-hydroxytryptamine (5-HT) from platelets [7, 8] , prolactin from anterior pituitary cells [9] , insulin from pancreatic islets [10] and catecholamines from adrenal chromaffin cells [11] . However, there are conflicting reports concerning the nature of the biochemical mechanisms associated with these secretory responses. For example, it has been clearly demonstrated that mastoparaninduced secretion of histamine from peritoneal mast cells occurs via a pertussis-toxin-sensitive G-protein-dependent activation of phospholipase C (PLC) [5, 6] , whereas catecholamine release from mastoparan-stimulated chromaffin cells occurs as a consequence of cell lysis [12] . In addition, mastoparan can attenuate receptor-mediated PLC activation, apparently both by affecting a pertussis-toxin-insensitive G-protein linked to phosphoinositide-specific PLC [13] and by a direct interaction with membrane-associated polyphosphoinositides [14] . The evidence drawn from studies at the cellular level therefore suggests that mastoparan directly or indirectly modulates PLC activity.
There is currently substantial evidence from platelet studies to support G-protein involvement in the receptor-mediated stimulation of phosphatidylinositol 4,5-bisphosphate hydrolysis by PLC (reviewed in [15, 16] ). In the present study, we have investigated the functional consequences of exposing human platelets to mastoparan in an attempt to define its mode of action, and to examine its usefulness as a specific probe of Gprotein-dependent events involved in the platelet activation cascade. We show that mastoparan induces secretion of platelet granule constituents, but that this secretory event is not linked to mobilization of intracellular Ca2' or to phosphorylation of the 45 and 20 kDa proteins normally associated with platelet activation. In addition, mastoparan increases intra-platelet cyclic AMP and results in the parallel phosphorylation of a protein with an apparent molecular mass of approx. 24 kDa. To our Abbreviations used: 5-HT, 5-hydroxytryptamine; PLC, phospholipase C; BTG, /1-thromboglobulin; PGI2, prostacyclin ( Vol. 281 knowledge, mastoparan represents the first agent that increases cyclic AMP and simultaneously causes granule secretion in human platelets.
MATERIALS AND METHODS

Materials
Mastoparan (INLKALAALAKKIL) was synthesized and purified by reverse-phase h.p.l.c. The purified peptide was dissolved in 0.9 % NaCl and appropriately diluted from a stock solution of 2 
Preparation of labelled washed platelet suspensions
Human blood was drawn from healthy volunteers, who had denied taking medication for at least 10 days, into 3.2 % (w/v) trisodium citrate (1 vol.) by forearm venepuncture and was centrifuged at 800 g for 15 min at room temperature to yield platelet-rich plasma as described previously [17] . In some experiments the platelet-rich plasma was preincubated with [14C]5-HT (0.1 uCi/ml) for 20 min at 37°C (see below). In all experiments, platelet-rich plasma was subsequently acidified to pH 6.5 with 0.1 M-citric acid, centrifuged at 1500 g for 10 min, and the pellet was resuspended in a pH 6.5 buffer consisting of 36 mM-citric acid, 103 mM-NaCl, 5 [18] . Briefly, platelet-rich plasma was incubated with [14C]5-HT (0.1 tCi/ml for 20 min at 37°C) and subsequently acidified to pH 6.5 as described above. After centrifugation (1500 g, 10 min) the resulting platelet pellet was resuspended in a glutamate-based permeabilizing buffer containing 15-20 ,uCi of myo-[3H]inositol/ml. Cells were electropermeabilized at 7 kV/cm (7 [17] , except that separation was carried out on gradient gels (7-20 %) and dried gels were autoradiographed at -80 'C by using Fuji RX X-ray film.
Saponin studies
Permeabilization of washed platelets with saponin was carried out as described by Authi et al. [20] . An [20] . Mastoparan Fig. 1 ) and 4-5 min respectively (means+S.E.M., n = 3). Mastoparan-induced secretion from both granule populations was not an artifact of centrifugation, since platelet suspensions were fixed with EDTA/formaldehyde (see the Materials and methods section) before the centrifugation step.
Further studies were carried out to determine the mechanism(s) responsible for mastoparan-induced exocytosis. Platelets preloaded with fura 2 were used to ascertain whether secretion caused by mastoparan was associated with increases in cytosolic Ca2'. Mastoparan (1-30 IM) caused no apparent change in the fluorescence of fura 2-loaded platelets in either the presence (1 mM) or the absence (1 mM-EGTA) of extracellular Ca2+ (Fig.  2) . In parallel incubations, thrombin (0.2 unit/ml) increased intracellular Ca2' to between 600 and 800 nm above resting levels. Similar results were obtained in thrombin-stimulated platelets in the absence of extracellular Ca2', except that the peak Ca2+ returned more rapidly to basal levels. In addition, mastoparan caused no decrease in the fluorescence monitored at an excitation wavelength of 360 nm, an event which is associated with increased membrane leakiness (e.g. [24] ) (Fig. 2 ).
Experiments were also performed to examine whether mastoparan promoted the release of adenine nucleotides from the cytosol. In platelets in which the cytosolic ATP pool was labelled by preincubation with [3H]adenine (90 min; 10 ,uCi/ml), mastoparan (1-30,UM) caused no release of [3H]adenine metabolites into the platelet supernatant.
The effects of the protein kinase inhibitor staurosporine were examined to determine the role of protein kinase activation in mastoparan-induced secretion (Table 1) . Preincubation for I min with 50 nM-staurosporine, a concentration previously shown to inhibit maximally phorbol myristate acetate-induced phosphorylation of the 45 kDa protein kinase C substrate [25] and potently to decrease exocytosis in response to a range of stimulatory platelet agonists [26, 27] , caused no decrease in ['4C]5-HT secretion induced by mastoparan. Moreover, at staurosporine concentrations of 1 ,UM and above, at which myosin light-chain kinase [26] and the cyclic nucleotide-dependent kinases [28] are also inhibited, mastoparan-induced dense-granule secretion remained completely unaffected ( Effects of prostacycin on dense-granule secretion induced by thrombin and mastoparan
The results from secretion experiments performed under conditions identical with those described above are given in Table 2 (1-30 ,uM) . Representative data for platelets exposed to mastoparan (1-30 /tM) for I min are included in Figs.  4(a) and 4(b) . However, in parallel with our ability to detect increased cyclic AMP levels, mastoparan appeared to enhance the incorporation of 32P into a protein of approx. 24 kDa (Figs.  4a and 4b ). In additional experiments in which the effects of mastoparan were compared directly with those of PGI2 (Fig. 4b) , both agents enhanced phosphorylation of a 24 kDa protein  (lanes d, e, g and h) , whereas elevated 32P incorporation into a 50 kDa protein was seen only in the presence of PGI2 (lanes g and h).
DISCUSSION
There is growing evidence drawn from studies in several cell types that mastoparan can affect cellular function through direct or indirect interaction with membrane-associated G-proteins; as such, this agent has potential value as a biochemical tool for probing G-protein-dependent processes. However, the mechanisms through which cellular activation is achieved appear to differ considerably between cell types. In intact rat peritoneal mast cells, mastoparan transiently stimulates PLC-catalysed phosphatidylinositol 4,5-bisphosphate hydrolysis, and inositol phosphate formation, through a pertussis-toxin-sensitive mechanism [6] . These findings strongly suggest the involvement of a G-protein(s) in the stimulatory action of mastoparan on these cells and substantiate the studies in vitro by Higashijima et al. [3, 4] in which mastoparan was suggested to interact directly with, and enhance the activity of, the pertussis-toxin-sensitive Gproteins Gi and Go. In contrast, mastoparan has also been reported to exert both stimulatory and inhibitory effects on PLC which are not modulated by pertussis-toxin pre-treatment [30, 13, 14] , raising the possibility that mastoparan can additionally interact with pertussis-toxin-insensitive substrates and/or that this agent can affect cellular processes by a mechanism(s) unrelated to its direct action on G-protein function.
In the present study, we describe the effects and possible mechanism of action of mastoparan on intact human platelets. During the course of these studies, Ozaki et al. [8] or an elevation of cytosolic [Ca2+] . In the present study, mastoparan at an equivalent concentration caused a greater level of dense-granule release (25-45 %) , which was complete within 1 min of exposure and which was accompanied by the release of a-granule constituents. This secretory response occurred in the complete absence of either shape change or aggregation and, in agreement with Ozaki et al. [8] , was observed under conditions where no liberation of arachidonic acid or increases in cytosolic [Ca2+] were detected. The absence of mastoparan-stimulated arachidonate release suggests that the actions of this agent in intact platelets do not include direct or indirect activation of phospholipase A2, as has been demonstrated in vitro [1] .
The present studies have also shown that exposure of platelets to mastoparan neither stimulated inositol phosphate formation nor enhanced phosphorylation of the 45 and 20 kDa proteins normally associated with platelet activation [15] . These results suggest that the mechanism whereby mastoparan elicits exocytosis is not dependent upon changes in PLC activity. Since most physiological platelet stimulants (e.g. thrombin, thromboxane A2) elevate PLC activity, secretion in response to these agonists has been shown without exception to be either decreased or abolished, both by agents which inhibit protein kinase C, and by PGI2, which decreases platelet activation, at least in part, by a cyclic AMP-mediated inhibition of PLC [15, 16] . A PLCindependent mechanism of exocytosis is therefore further supported by the observation that mastoparan-induced secretion was insensitive to both prostacyclin and the protein kinase C inhibitor staurosporine. In addition, micromolar concentrations of staurosporine inhibit myosin light-chain kinase [26] , the cyclic nucleotide-dependent kinases [28] and some tyrosine kinases [31] , suggesting that the secretory response to mastoparan is also unrelated to the activation of these enzymes. Furthermore, secretion was not due to cell lysis, since mastoparan caused no release of [3H]adenine and its metabolites from prelabelled platelets and did not result in a decreased fluorescence of fura 2-loaded platelets monitored at 360 nm. A mechanism of secretion involving activation of phospholipase D is also unlikely to contribute to the secretory activity of mastoparan, since recent evidence suggests that stimulation of human platelet phospholipase D occurs primarily as a consequence of PLC activation [32, 33] . From our findings, it seems reasonable to postulate that mastoparan promotes exocytosis by at least two possible mechanisms. First, mastoparan may exert a direct fusogenic action resulting from insertion of its hydrophobic domain into the plasma membrane; this effect may or may not be dependent on its subsequent interaction with G-protein(s). Secondly, and equally tenable, secretion may result from stimulation of the putative G-protein Ge which is linked directly to exocytosis in a number of cell types and which has been reported to be responsible for the secretory response observed in the absence of PLC activation and Ca2+ mobilization [34, Ozaki et al. [8] have reported that mastoparan-induced 5-HT secretion from digitonin-permeabilized platelets is pertussistoxin-sensitive. However, mastoparan clearly does not activate PLC in intact platelets, suggesting that a G-protein(s) other than the putative GP is involved in this response. Whether Ge is a pertussis-toxin substrate is unclear at present. However, based on the observation that mastoparan-induced histamine release in mast cells occurs in the absence of PLC stimulation and is attenuated by pertussis toxin, Aridor et al. [41] have proposed that Ge may be a member of the Gi G-protein family. Similarly, a pertussis-toxin-sensitive G-protein seems to play an inhibitory role in modulating the final stages of the exocytotic process in adrenal chromaffin cells [42] . Clearly, further studies to evaluate the mechanism of mastoparan-induced secretion in human platelets are required.
The reported ability of mastoparan to stimulate the activities of purified Gi and G. [3] [48] and the fl-chain of glycoprotein lb (GPlb) [49] respectively. In the present study, the rise in [ 
